Hemodialysis group | Control group | Statistical significance | |
---|---|---|---|
(N = 104) | (N = 14) | ||
Age (years) | 53.6 (50.3-56.9) | 54.6 (45.1-64.1) | 0.93 |
Gender (male/female) | 56/48 | 6/8 | 0.63 |
Body mass index (kg/m 2 ) | 24.9 (23.3-26.6) | 24.7 (23.9-25.6) | 0.82 |
Obesity (BMI ≥ 30 kg/m2) (n/%) | 11 / 10.6 | 0 | 0.43 |
Smokers (n/%) | 62 / 59.6 | 1 / 7.1 | <0.001 |
Smoking burden (pack-years) | 15 (12–18) | ||
Family burden (n/%) | 32 / 30.8 | NA. | |
Primary cause of CKD (n/%) | |||
Diabetes | 11 / 10.6 | ||
Hypertension | 4 / 3.8 | ||
Nephrolithiasis | 3 / 2.9 | ||
Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 6 / 5.8 | ||
Ischemic nephropathy | 5 / 4.8 | ||
Glomerulonephritis | 50 / 48.1 | ||
Urinary tract infection | 6 / 5.8 | ||
Amyloidosis | 3 / 2.9 | ||
Other or unknown | 16 / 15.4 | ||
Time on dialysis (months) | 45 (33–54) | ||
Kt/V (per HD session) | 1.29 (1.25-1.34) | ||
Co-morbidity (%) | |||
Hypertension | 87 / 84.5 | 0 | |
Diabetes | 19 / 18.3 | 0 | |
Coronary artery disease | 35 / 33.7 | 0 | |
Stroke | 9 / 8.7 | 0 | |
Past kidney transplantation | 18 / 17.3 | - | |
Pharmacotherapy (n/%) | |||
Antihypertensive | 79 / 76.0 | ||
No of antihypertensive drugs (n) | 2.0 (1.7-2.2) | ||
Oral anti-diabetic* | 5 / 26.3 | ||
Insulin* | 14 / 73.7 | ||
Antiplatelet | 52 / 50.0 | ||
Oral anticoagulant | 9 / 8.7 | ||
Statins | 18 / 17.3 | ||
Fibrates | 0 | ||
Oral phosphorous binders | 102 / 98.1 | ||
Carbonate calcium dose (g/day) | 3.3 (2.9-3.7) | ||
Sevelamer hydrochloride (g/day) | 0 | ||
Alfacalcidol | 82 / 78.8 | ||
Alfacalcidol dose (μg/week) | 2.5 (1.1-3.8) |